摘要
目的研究CCAAT增强子结合蛋白δ(CEBPD)在前列腺癌组织中的表达,分析其表达与临床病理特征的关系。方法通过免疫组织化学技术检测前列腺癌组织芯片中的CEBPD表达情况,结合Taylor数据库,分析CEBPD的表达水平与前列腺癌患者临床病理特征和生存期的关系。结果前列腺癌患者组织中CEBPD表达与患者的年龄(P=0.041)、格里森(Gleason)评分(P<0.01)、临床分期(P=0.018)、是否转移(P<0.01)、是否死亡(P=0.029)、是否生化复发(P<0.01)呈负相关,CEBPD低表达的前列癌患者的无生化复发生存率显著降低(P<0.01),单因素和多因素COX回归分析显示CEBPD高表达的前列腺癌患者的生化复发的风险较低(单因素:P<0.01;多因素:P=0.032)。结论CEBPD在前列腺癌组织中表达与癌症的进展与临床预后相关,有望成为前列腺癌新的生物标记物。
Objective To study the expression of CCAAT enhancer binding protein delta(CEBPD)in prostate cancer and analyze the relationship between its expression and clinicopathological characteristics.Methods The expression of CEBPD in prostate cancer tissue microarray was detected by immunohisto-chemistry,and the relationship between the expression level of CEBPD and the clinicopathological characteristics and survival period of prostate cancer patients was analyzed by combining with Taylor database.Results The CEBPD expression in prostate cancer patients was correlated with age(P=0.041),Gleason score(P<0.01),clinical stage(P=0.018),metastasis(P<0.01),death(P=0.029),biochemical recurrence(P<0.01).The biochemical recurrence-free survival rate of prostate cancer patients with lower CEBPD expression decreased significantly(P<0.01).Conclusion The expression of CEBPD in prostate cancer tissues is related to cancer progression and clinical prognosis and is expected to be a new biomarker.
作者
凌济忠
张玉婷
习明
万颂
华伟
江敏耀
万跃平
LING Jizhong;ZHANG Yuting;XI Ming;WAN Song;HUA Wei;JIANG Minyao;WAN Yueping(Department of Surgery,Huashan Town Health Center,Guangzhou 510880,China;Nanshan Class,Nanshan School,Guangzhou Medical University,Guangzhou 511436,China;Department of Urology,Huadu District People's Hospital,Southern Medical University,Guangzhou 510800,China)
出处
《广东药科大学学报》
CAS
2020年第1期124-127,F0003,共5页
Journal of Guangdong Pharmaceutical University
基金
广东省科技计划项目(2014A020212471)
广州市科技计划项目(201607010398)
花都区科技计划项目(HD15CXY005,15-HDWS-068)
